Publication: El receptor cannabinoide CB₂R como diana terapéutica y herramienta pronóstico/predictiva en cáncer de mama HER2+
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-05-21
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El cáncer de mama es una de las enfermedades más frecuentes en todo el mundo y representa un importante problema de salud pública. Se trata de una enfermedad muy heterogénea que se clasifica en distintos subtipos atendiendo a marcadores moleculares. Uno de ellos se caracteriza por la sobre expresión del receptor del factor de crecimiento epidérmico 2 (HER2), y representa un 20%-25% de todos los cánceres de mama diagnosticados. Aunque estos tumores son muy agresivos, el pronóstico de las pacientes ha mejorado enormemente con el desarrollo de terapias dirigidas contra este receptor. Sin embargo, las tasas de resistencia innata y adquirida son muy elevadas y, por tanto, sigue siendo necesaria la búsqueda de tanto nuevos tratamientos para estas pacientes, como de herramientas que permitan la identificación temprana de aquellas con alto riesgo de no responder a terapias estándar o de recaer..
Breast cancer is one of the most frequent malignancies worldwide and represents an important public health problem. This disease is very heterogeneous and is subclassified in different subtypes according to molecular markers. One of them is characterized by the over expression of the human epidermal growth factor receptor 2 (HER2), and represents 20%–25% of all breast carcinomas. Although these tumors are very aggressive, the clinical outcome of HER2+ breast cancer patients has greatly improved with the development of targeted therapies against this receptor. However the innate and acquired resistance rates to these therapies are still significant and therefore, new therapies are urgently warranted for these patients as well as new tools to identify those at a higher risk of not responding or recurring...
Breast cancer is one of the most frequent malignancies worldwide and represents an important public health problem. This disease is very heterogeneous and is subclassified in different subtypes according to molecular markers. One of them is characterized by the over expression of the human epidermal growth factor receptor 2 (HER2), and represents 20%–25% of all breast carcinomas. Although these tumors are very aggressive, the clinical outcome of HER2+ breast cancer patients has greatly improved with the development of targeted therapies against this receptor. However the innate and acquired resistance rates to these therapies are still significant and therefore, new therapies are urgently warranted for these patients as well as new tools to identify those at a higher risk of not responding or recurring...
Description
Tesis de la Universidad Complutense de Madrid, Facultad de Ciencias Biológicas, leída el 16-11-2018